Kyverna Therapeutics (KYTX) Expected to Announce Earnings on Tuesday

Kyverna Therapeutics (NASDAQ:KYTX) is projected to announce its earnings results before the market opens on Tuesday, March 25th. Analysts expect the company to announce earnings of ($0.84) per share for the quarter.

Kyverna Therapeutics Stock Performance

Shares of NASDAQ:KYTX opened at $2.38 on Friday. Kyverna Therapeutics has a 52-week low of $2.20 and a 52-week high of $25.98. The business has a 50-day moving average price of $2.95 and a 200-day moving average price of $4.32.

Institutional Trading of Kyverna Therapeutics

A hedge fund recently raised its stake in Kyverna Therapeutics stock. Bank of America Corp DE increased its stake in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) by 41.6% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 21,788 shares of the company’s stock after acquiring an additional 6,400 shares during the quarter. Bank of America Corp DE owned approximately 0.05% of Kyverna Therapeutics worth $81,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 18.08% of the company’s stock.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.